Stock Alert for Crowne Ventures Inc. (CRWV)
  • Stock Alert for Crowne Ventures Inc. (CRWV)
  • Stock Alert for Eco Ventures Group Inc. (EVGI)
  • " />

    Stock Alert for Mistral Ventures Inc. (MILV)

    Mistral Ventures Inc. (Pink: MILV), a development-stage company, was engaged in the acquisition, exploration and development of natural resource properties. During the year ended December 31, 2007, the Company’s operations were focused on exploratory mining operations and identifying a suitable business opportunity for acquisition. On February 9, 2006, the Company purchased the Gold Bug Project. This property consisted of six mineral cell claims having a total surface area of approximately 315 acres in Beaverdell, British Columbia, Canada. As of December 31, 2007, the Company had no interests in any mineral properties. In October 2011, the Company acquired 100% interest in Nature’s Bioceuticals Inc.

    Share Statistics (27-Oct-11)
    Symbol MILV
    Current price $0.06
    52wk Range: $0.0015 – $0.07
    Avg Vol (3m): 872,188
    Market Cap. 21.12M
    Shares Outstanding 347.45M

    Source: Reuters.com, SEC Filings.

    Investment Highlights

    MILV shares spiked as much as 33% to $0.06 yesterday as volume soared by roughly 655 times its 30-day average.

    Shares in MILV have gained 21.6% in the last five days; 204.0% in the last month; and 1,251.1% year-to-date.

    MILV shares were initially boosted last week following news that it has completed the acquisition of 100% of Nature’s Bioceuticals, a developer and acquirer of rights to natural medicine formulas treating specific medical conditions

    Nature’s Bioceuticals, which line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, will operate as a wholly owned subsidiary of MILV.

    As MILV stated, Nature’s Bioceuticals is the first of many acquisitions that the Company is going to make in the rapidly expanding natural medicine market.

    Nature’s Bioceuticals on Thursday announced it has reached an agreement with the inventor of a cold and flu medicine that has been in development for many years. According to Robert deZanger, CEO of Nature’s Bioceuticals, the formula, which contains over twenty different herbs that are all ‘active ingredients,’ provides relief from the cold and flu symptoms, but more importantly, it boosts the body’s immune response to combat the cause of the virus.

    “Although the cold and Flu market is flooded with a number of established brands, we are confident that we can capture a significant portion of the market with an all natural product that really works,” deZanger said.

    Source: http://www.naturesbioceuticals.com/index.php/investor-relations

    Financial Summary

    MILV is a development stage company and has not reported receiving revenues from operating activities.

    Technical Analysis

     

    Source: http://stockcharts.com

    MILV is presently near its upper Bollinger Band. This suggests that it is at a high level relative to recent action.

    The MACD for MILV currently indicates a strong bullish signal for two reasons. First, the MACD is above the signal line, a 9-day moving average. Second, the MACD is above 0 which implies that the underlying moving averages are trending higher.

    Comparative Analysis

    No Direct Competitor Comparison.

    DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

    The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

    Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

    Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

    Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

    We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

    To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

    We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

    Leave a Reply

    Your email address will not be published. Required fields are marked *